Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2016

View Archived Issues

New animal models of ocular diseases presented at ARVO

Aptahem collaborates with Nencki Institute of Experimental Biology on APTA-1

Regen Biopharma starts preclinical development of universal donor immunotherapy

Selecta Biosciences obtains exclusive license for gene therapy vector Anc-80

Response, safety data updated for cancer vaccine INO-3112 in HPV-associated HNSCC trial

Otsuka Pharmaceutical reviews pipeline highlights of first quarter 2016

Eisai reviews pipeline highlights of fourth quarter of fiscal 2015

FDA grants orphan drug designation to ANAVEX 2-73 for the treatment of Rett syndrome

Halozyme anti-EGFR ADC is active against tumors with resistance mutations

Stratatech initiates first-in-human study of ExpressGraft-C9T1 skin tissue for diabetic foot ulcers

Ohio State University patents MPS1 inhibitors

University Health Network discloses RIP-2 inhibitors

DS Biopharma to develop DS-102 for COPD as well as NASH

Wisconsin Alumni Research Foundation reports HIV protease inhibitors

Xencor generates bispecific antibodies targeting prostate-specific membrane antigen and CD3

Ube Industries presents CDK7 inhibitors

Bristol-Myers Squibb describes alpha7 nicotinic acetylcholine receptor ligands

EMA accepts MAA for Pfizer's Trumenba

Avalon Ventures and GSK form new company, PDI Therapeutics

Acorda Therapeutics discontinues development of Plumiaz

NanoCarrier describes NC-6201, an anticancer product based on the ADCM platform

Cyramza receives additional indication approval for colorectal cancer in Japan

Pfizer initiates phase I trial of PF-06817024

NMDA receptor antagonist for colitis

Ustekinumab receives FDA orphan designation for pediatric Crohn's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...